ERBB4 G1109C

CI-VAR-00001572Explore in graph →ENST00000342788.4:c.3325G>TCIViC 1673

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma2
ERBB4 G1109C	Afatinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID9676 This retrospective preclinical study assessed the efficacy of afatinib towards head-and-neck squamous cell carcinoma (HNSCC) human cell lines expressing ERBB4 (HER4) G1109C mutation. According to the … (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic
ERBB4 G1109C	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID4809 In an in vitro study, a head and neck squamous cell carcinoma cell line SAS expressing ERBB4 (HER4) G1109C was associated with insensitivity to erlotinib treatment (IC50=1.47uM). Resistance was determ… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
ERBB4 G1109C	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID9677 Multiple retrospective preclinical experiments were investigating the functional role of ERBB4 (HER4) G1109C mutation in various cell lines. HEK293 and NIH3T3 cell lines expressing either ERBB4 (HER4)… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic